Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema

Trial Profile

Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Retinal oedema
  • Focus Adverse reactions
  • Acronyms ACME
  • Most Recent Events

    • 08 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
    • 04 Oct 2018 Planned End Date changed from 1 Jun 2019 to 1 Sep 2020.
    • 04 Oct 2018 Planned primary completion date changed from 1 Mar 2019 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top